---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-179447"
form_type: "8-K"
ticker: "BLCO"
cik: "0001860742"
company_name: "Bausch & Lomb Corp"
filed_at: "2023-06-30T23:59:59+00:00"
generated_at: "2026-06-13T14:22:38.494470+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Bausch + Lomb agrees to acquire XIIDRA from Novartis for up to $2.5B

## Summary
- Upfront cash $1.75B plus up to $750M in milestones; total consideration up to $2.5B.
- XIIDRA generated ~$487M in sales in 2022; patented through 2033.
- Acquisition includes libvatrep (Phase 2b) and AcuStream device.
- Expected close by end of 2023; immediately accretive; J.P. Morgan committed financing.
- B+L expects to return to current leverage within ~24 months post-close.

## SEC filing metadata
- accession: 0001193125-23-179447
- form_type: 8-K
- ticker: BLCO
- cik: 0001860742
- company_name: Bausch & Lomb Corp
- filed_at: 2023-06-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860742/000119312523179447/0001193125-23-179447-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860742/000119312523179447/d493799d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-179447
- JSON: https://secwatch.observer/filing/0001193125-23-179447.json
- Plain text: https://secwatch.observer/filing/0001193125-23-179447.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.